Total Payments
$100,936
2023 Payments
$12,059
Companies
16
Transactions
82
Medicare Patients
24
Medicare Billing
$838.38
Payment Breakdown by Category
Research$72,837 (72.2%)
Other$14,800 (14.7%)
Consulting$10,090 (10.0%)
Travel$2,019 (2.0%)
Food & Beverage$952.10 (0.9%)
Education$237.60 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $72,837 | 44 | 72.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,000 | 2 | 11.9% |
| Consulting Fee | $10,090 | 7 | 10.0% |
| Travel and Lodging | $2,019 | 9 | 2.0% |
| Grant | $2,000 | 1 | 2.0% |
| Food and Beverage | $952.10 | 13 | 0.9% |
| Honoraria | $800.00 | 1 | 0.8% |
| Education | $237.60 | 5 | 0.2% |
Payments by Type
Research
$72,837
44 transactions
General
$28,098
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Circassia Pharmaceuticals Inc | $42,219 | 9 | $0 (2017) |
| Lupin Inc. | $27,053 | 6 | $0 (2018) |
| GENZYME CORPORATION | $14,000 | 3 | $0 (2023) |
| Genentech USA, Inc. | $4,689 | 6 | $0 (2019) |
| Merck Sharp & Dohme LLC | $4,425 | 2 | $0 (2022) |
| Eli Lilly and Company | $1,544 | 2 | $0 (2020) |
| Sandoz Inc. | $1,500 | 1 | $0 (2017) |
| CSL Behring | $1,082 | 7 | $0 (2019) |
| Theravance Biopharma Inc. | $976.00 | 5 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $937.46 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $12,059 | 3 | GENZYME CORPORATION ($12,000) |
| 2022 | $1,725 | 2 | Merck Sharp & Dohme LLC ($1,635) |
| 2021 | $4,840 | 3 | Merck Sharp & Dohme Corporation ($2,790) |
| 2020 | $8.36 | 1 | Eli Lilly and Company ($8.36) |
| 2019 | $7,697 | 15 | Genentech USA, Inc. ($4,689) |
| 2018 | $29,108 | 33 | Lupin Inc. ($27,053) |
| 2017 | $45,499 | 25 | Circassia Pharmaceuticals Inc ($42,219) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/06/2023 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $58.53 | General |
| Category: Inflammation | ||||||
| 01/30/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| 01/30/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| 09/26/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $90.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/29/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,635.00 | General |
| 11/29/2021 | GENZYME CORPORATION | — | Grant | Cash or cash equivalent | $2,000.00 | General |
| 11/26/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $2,790.00 | General |
| 11/15/2021 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $50.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/06/2020 | Eli Lilly and Company | — | — | In-kind items and services | $8.36 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | ||||||
| 11/21/2019 | Eli Lilly and Company | — | — | In-kind items and services | $1,535.50 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | ||||||
| 10/26/2019 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $197.66 | General |
| Category: Immunology | ||||||
| 10/25/2019 | Genentech USA, Inc. | Xolair (Biological) | Consulting Fee | Cash or cash equivalent | $3,795.00 | General |
| Category: Immunology | ||||||
| 10/25/2019 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $416.77 | General |
| Category: Immunology | ||||||
| 10/25/2019 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $202.59 | General |
| Category: Immunology | ||||||
| 10/25/2019 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | Cash or cash equivalent | $67.00 | General |
| Category: Immunology | ||||||
| 10/25/2019 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | Cash or cash equivalent | $9.50 | General |
| Category: Immunology | ||||||
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $245.37 | General |
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $54.07 | General |
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $50.57 | General |
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | Cash or cash equivalent | $21.19 | General |
| 03/14/2019 | Teva Pharmaceuticals USA, Inc. | Fluticasone Propionate and Salmeterol (Drug) | — | Cash or cash equivalent | $196.25 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma • Category: Respiratory | ||||||
| 01/22/2019 | CSL Behring | Haegarda (Biological) | Honoraria | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 01/22/2019 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $44.48 | General |
| Category: Immunology | ||||||
| 01/21/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $60.84 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 06/21/2018 | Regeneron Pharmaceuticals, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | — | In-kind items and services | $42.47 | Research |
| Study: A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $36,313 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $24,553 | 5 |
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $5,906 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $2,500 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | Eli Lilly and Company | $1,544 | 2 |
| A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model | Regeneron Pharmaceuticals, Inc. | $925.40 | 9 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 | SANOFI US SERVICES INC. | $899.49 | 17 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $196.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 12 | 12 | $970.00 | $326.26 |
| 2020 | 1 | 12 | 12 | $1,884 | $512.12 |
Total Patients
24
Total Services
24
Medicare Billing
$838.38
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 12 | 12 | $970.00 | $326.26 | 33.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 12 | 12 | $1,884 | $512.12 | 27.2% |
About Dr. Anthony Montanaro, MD
Dr. Anthony Montanaro, MD is a Allergy & Immunology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720185598.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Montanaro, MD has received a total of $100,936 in payments from pharmaceutical and medical device companies, with $12,059 received in 2023. These payments were reported across 82 transactions from 16 companies. The most common payment nature is "" ($72,837).
As a Medicare-enrolled provider, Montanaro has provided services to 24 Medicare beneficiaries, totaling 24 services with total Medicare billing of $838.38. Data is available for 2 years (2020–2021), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Portland, OR
- Active Since 09/20/2006
- Last Updated 07/10/2007
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1720185598
Products in Payments
- TIOTROPIUM (Drug) $24,553
- Xolair (Biological) $4,689
- ADVAIR (Drug) $2,500
- SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE (Drug) $1,500
- DUPIXENT DUPILUMAB INJECTION (Biological) $925.40
- SAR440340 (Drug) $899.49
- Haegarda (Biological) $844.48
- FEVIPIPRANT (Drug) $566.26
- Berinert 500U (Biological) $237.60
- ANORO (Drug) $230.00
- Fluticasone Propionate and Salmeterol (Drug) $196.25
- NUCALA (Biological) $140.00
- Xhance (Drug) $60.84
- TEZSPIRE (Biological) $58.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Portland
Michael Osborne, M.d, M.D
Allergy & Immunology — Payments: $10,239
Allergy & Immunology $10,239
Dr. Renganathan Srinivasan, M.d, M.D
Allergy & Immunology — Payments: $6,425
Allergy & Immunology $6,425
Cristina Swanson, M.d, M.D
Allergy & Immunology — Payments: $3,166
Allergy & Immunology $3,166
Karen Anstey, M.d, M.D
Allergy & Immunology — Payments: $3,002
Allergy & Immunology $3,002
Dr. Michael Noonan, Md, MD
Allergy & Immunology — Payments: $2,815
Allergy & Immunology $2,815
Dr. Laurel Anderson Cowell, Md, MD
Allergy & Immunology — Payments: $1,112
Allergy & Immunology $1,112